AbbVie stock: Q3 revenue rises as 2026 guidance moves higher

AbbVie reported third-quarter results on Friday, October 30, and raised its full-year adjusted earnings outlook. The release from AbbVie also highlighted regulatory progress for its oncology pipeline and a higher dividend for 2027.

Results support higher guidance

For the quarter ended September 30, worldwide net revenue reached USD 17.404 billion, up 10.3 percent from a year earlier. Immunology revenue rose 16.3 percent to USD 9.165 billion, while neuroscience revenue increased 19.4 percent to USD 3.389 billion. Oncology revenue was nearly flat at USD 1.696 billion, with Venclexta and Elahere growth partly offset by lower Imbruvica revenue.

Reported diluted earnings per share came to USD 2.37, while adjusted diluted earnings per share were USD 3.82. The adjusted figure included an unfavorable USD 0.11-per-share impact from acquired research, development and milestone expenses.

AbbVie lifted its 2026 adjusted diluted EPS range to USD 13.95-13.99 from USD 13.76-13.96. The revised range includes a USD 0.69-per-share impact from acquired research, development and milestone expenses incurred through the first nine months.

Etentamig reaches FDA review

AbbVie said it submitted a Biologics License Application for etentamig, an investigational BCMA x CD3 bispecific T-cell engager for adults with relapsed or refractory multiple myeloma. The filing is supported by the Phase 3 CERVINO study, which reported a 74 percent overall response rate and a 60 percent reduction in the risk of progression or death versus investigator's choice of standard therapies.

The company said etentamig uses one step-up dose followed by monthly dosing. FDA submission does not guarantee acceptance or approval, leaving regulatory review as the next milestone for the program.

Stock context for investors

AbbVie stock traded at EUR 265.75 on Lang & Schwarz at 16:10 CET on Friday, October 30, 2026. That was 2.25 percent above the EUR 259.90 quote in the October 29 report, a separate comparison from any Xetra session move.

The real-time quote of AbbVie stock remains relevant as investors weigh stronger near-term sales against patent pressure on mature products and the cost of pipeline expansion.

Broader sentiment can be followed through the S&P 500 market overview.

More news and analyses on AbbVie stock will follow as the FDA process and the next earnings milestones develop.